4.3.2 Shifting Role of Diagnostics
4.3.3 Multiplexing and Foundation One
4.3.4 The Disruption Dynamic
4.3.6 The Next Five Years
5. Cancer Immuno-Oncology Diagnostics Recent Developments
5.1 Recent Developments - Importance and How to Use This Section
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
Qiagen Expands Immuno-Oncology Portfolio
IncellDx Awarded PD-L1 Detection Patent
FDA Approves CDx for Trastuzumab
Promega Nabs CE Mark for Microsatellite Instability IVD
ArcherDx partners with AstraZeneca for Immuno-Oncology
Germline Results Guides Precision Therapy
Agilent PD-L1 Assay Gets FDA Approval
Bayer, OrigiMed Form Companion Diagnostic Development Alliance
Bio-Me to Develop Microbiome Biomarker Test for Cancer Immunotherapy
SkylineDx, BioInvent Collaborate to Characterize Predictive Immunological
4.3.3 Diagnostics Moves Out of the Hospital
4.3.4 Disruption Looms
5. PCR Recent Developments
5.1.1 Importance of These Developments
5.1.2 How to Use This Section
Scope Fluidics Secures ?6.2M Supporting Rapid MDx
Quidel Expects SARS-CoV-2 Testing Demand to Continue Through 2022, and Beyond
Malaria Assays Use CRISPR for Point-of-Care Multispecies Detection
Fluidigm Saliva Test for SARS-CoV-2 Uses Extraction-free RT-PCR
Visby Medical Gonorrhea Test Wins $19M AMR Diagnostic Competition
HelixBind Receives $3M NIH Grant to Expand Bloodstream Infection Dx Platform
Israel s Nucleix Targeting US Market With Noninvasive Bladder, Lung Cancer Assays
Thermo Fisher Sees Many Complementary Offerings in Qiagen Combination
DxTerity Gets CE Mark for At-Home Blood Sample Collection Device
Share this article
Share this article
ResearchAndMarkets.com s offering.
Sepsis was killing over 30 million people a year with no definitive diagnostic in hand. And now the COVID-19 Pandemic has increased the sepsis death toll. The race is on using all the genomic and molecular diagnostic tools that have come to the fore in the last decade. It is not clear who will be the winner, but the stakes are global and large. Emergency life-saving diagnostics can command a premium in the market, especially deaths related to COVID-19 infections. Understand the different drivers of this huge global diagnostic market and where the opportunity lies.